Pharma's Almanac TV
PA TV
Dashboard
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Analytics
Research
CDMO
CRO
Excipients
Pharmaceutical Equipment
Pharmaceutical Intermediates
Supply Chain Logistics
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
By The Numbers
Drug Development
550 Articles Available
1
23
Can't find what you're looking for? Try our
advanced search
.
Oncology
Dozens of Non-Oncology Drugs Can Kill Cancer Cells
PR-M01-20-NI-031
Cancer Breakthrough
Progress Report on Cancer Breakthroughs 2020 Project Presented by Dr. Soon-Shiong at J.P. Morgan Healthcare Conference
PR-M01-20-NI-026
Cancer Treatment
NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer Patient
PR-M01-20-NI-020
Drug Development
LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer
PR-M01-20-NI-003
FDA Approval
Allergan Receives FDA Approval for Migraine Treatment
PR-M01-20-NI-001
Drug Discovery Platform
Cellarity Founded to Identify New Drugs that Target Specific Cellular Behaviors
PAO-M12-19-NI-004
PR-M12-19-NI-018
FDA Grants Orphan Drug Designation to Epidermolysis Bullosa Treatment
Collaboration
AbbVie and Scripps Research Announce Collaboration to Develop a Broad Range of New Therapeutics
PR-M12-19-NI-021
Ophthalmology
Tackling Genetic Eye Diseases with Novel RNA Therapies
PAP-Q4-19-CL-027
Alzheimer's Disease
The Self-Protein Challenge
PAP-Q4-19-CL-002
Alzheimer's Disease
Innovating the Approach to Neurological Disease Treatment
PAP-Q4-19-CL-004
Antibody-Drug Conjugate
Increasing the Potency of Antibody–Drug Conjugates
PAP-Q4-19-CL-008
CAR-T
Leveraging Natural Killer Cells as CAR-T Therapies
PAP-Q4-19-CL-013
Photodynamic Therapy
Developing a Potential Cure for Bladder Cancer
PAP-Q4-19-CL-031
Bristol-Myers Squibb Announces Update for Patients with Resected High-Risk Melanoma and PD-L1 <1%
Gene Therapy
Ferring and Blackstone Life Sciences Invest Over $570 Million USD in Novel Gene Therapy for Bladder Cancer Patients
PR-M11-19-NI-032
Partnership
Asuragen Partners with Wave Life Sciences to Develop Companion Diagnostics for Huntington’s Disease
PR-M11-19-NI-030
Launch
Werewolf Therapeutics Launches with $56M Series A Financing to Develop Transformative Immuno-Stimulatory Cancer Medicines
PR-M11-19-NI-024
Drug Approval
Qtrilmet Approved in the EU for the Treatment of Type-2 Diabetes
PR-M11-19-NI-020
Clinical Results
VistaGen Reports Topline Phase 2 Results for AV-101 as an Adjunctive Treatment of Major Depressive Disorder
PR-M11-19-NI-019
Drug Development
WuXi Biologics Congratulates Tychan on the World’s First Yellow Fever Antibody Tested Safe and Efficacious in Human Volunteers
PR-M11-19-NI-018
Drug Development
Draft ICER Report Questions Cost-Effectiveness of New Migraine Drugs
PAO-M11-19-NI-004
Funding
Startup Gets Significant Funding to Support Novel Biosensing Technology
PAO-M11-19-NI-004
RNA
RNA Repressor Switches Off Protein Production
PAO-M11-19-NI-001
1
23
»
